Corporate governance

Executive management

Christine Lind

Born: 1974

Education: Bachelor of Science in Finance and Information Systems, New York University, Stern School of Business.  Masters in Business Administration in Finance and Management, Columbia Business School

Previous Assignments: Management roles in the life sciences industry, including VP Business Development at LifeCell Corporation, EVP Business Development and subsequently CEO of Medivir AB, Strategic Advisor to BioArctic AB, and most recently, SVP Corporate Development for SSI Strategy. Prior to that, as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co).

Other Assignments: Chairman of the Board, Mendus AB. Member of the Board, Xspray Pharma AB. Chairman and CEO, Lind Growth Strategy AB.

Patrick Bach

Employed: 2023

Born: 1983

Education: MSc in Finance and Strategic Management from Copenhagen Business School with graduating MSc courses at Columbia Business School, Harvard University, and The London School of Economics and Political Science. BSc in Economics and Business Administration from Copenhagen Business School.

Previous assignments: Various managerial positions at Atos Medical AB, most recently Managing Director Nordics and VP. Prior to that, several managerial positions at Coloplast, including Head of Strategy & NPWT Marketing, and Associate at McKinsey & Company as well as a Business Analyst at Novo Nordisk A/S.

Mikael Sander

Employed: 2023

Born: 1959

Education: Master of Science in Business & Economics, University of Gothenburg and MBA, University of Lund, Sweden

Previous assignments: Managerial positions at Dentsply Sirona (responsible for global digital implants business, global commercial and business Europe, North American and Asia, VP Sales, General Manager in Boston, and VP of Business Development in Mölndal, Sweden). Prior to that, commercial and management roles in operations, finance, and business development at Astra Zeneca and Astra Tech.

Other assignments: Board member Corticalis AS and Mevia AB.

Shareholdings: 10 868 B-shares as a personal holding and 288 182 call options

Nina Nornholm
Head of Corporate Communication & Investor Relations

Born: 1967

Education: Studies in Business Administration (Marketing and Communication) at Stockholm University

Previous assignments: More than 25 years of experience in the global financial industry with focus on strategic communication, branding, and investor relations. Head of Communications at private equity firm EQT 2007-2022. Prior to that, communication specialist roles at SEB Asset Management and investment bank Alfred Berg.

Other assignments: Board member Plan International Sweden.

Shareholdings: 36 023 call options